Arcus Biosciences Ownership | Who Owns Arcus Biosciences?
Arcus Biosciences Ownership Summary
Arcus Biosciences is owned by 93.91% institutional investors, 34.76% insiders. Gilead sciences is the largest institutional shareholder, holding 32.89% of RCUS shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 3.82% of its assets in Arcus Biosciences shares.
RCUS Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Arcus Biosciences | 93.91% | 34.76% | -28.67% |
| Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
| Industry | Biotech Stocks | 306.59% | 11.10% | -217.69% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Gilead sciences | 30.06M | 32.89% | $447.61M |
| Blackrock | 9.76M | 11.33% | $148.69M |
| Blackrock funding, inc. /de | 11.46M | 10.80% | $93.27M |
| Vanguard group | 5.39M | 5.90% | $80.25M |
| Point72 asset management | 5.97M | 5.62% | $48.57M |
| Fmr | 4.05M | 4.43% | $60.34M |
| Woodline partners lp | 3.52M | 3.86% | $52.47M |
| Suvretta capital management | 3.69M | 3.48% | $30.03M |
| State street | 2.99M | 3.28% | $44.58M |
| Invus financial advisors | 1.61M | 1.87% | $24.55M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Gilead sciences | 30.06M | 28.86% | $447.61M |
| Invus financial advisors | 1.61M | 27.51% | $24.55M |
| Dafna capital management | 627.63K | 1.41% | $5.11M |
| Sectoral asset management | 257.27K | 1.38% | $2.09M |
| Boxer capital | 1.60M | 1.28% | $24.40M |
| Suvretta capital management | 3.69M | 0.91% | $30.03M |
| Siren | 1.61M | 0.68% | $13.12M |
| Sofinnova investments | 1.22M | 0.61% | $9.90M |
| Parkman healthcare partners | 599.61K | 0.56% | $4.88M |
| Woodline partners lp | 3.52M | 0.35% | $52.47M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Gilead sciences | 30.06M | 28.86% | 30.06M |
| Point72 asset management | 5.97M | 0.10% | 3.10M |
| Suvretta capital management | 3.69M | 0.91% | 1.13M |
| Millennium management | 924.37K | 0.01% | 679.27K |
| Blackrock funding, inc. /de | 11.46M | 0.00% | 590.89K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Alliancebernstein | 72.51K | 0.00% | -1.23M |
| Braidwell lp | - | - | -802.10K |
| Decheng capital | 160.00K | 0.20% | -648.79K |
| Parkman healthcare partners | 599.61K | 0.56% | -616.02K |
| Schonfeld strategic advisors | 135.00K | 0.01% | -538.84K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Gilead sciences | 30.06M | 28.86% | 30.06M | $447.61M |
| Integral health asset management | 300.00K | 0.22% | 300.00K | $2.44M |
| Susquehanna portfolio strategies | 247.97K | 0.04% | 247.97K | $2.02M |
| Qube research | 84.05K | 0.00% | 84.05K | $684.16K |
| Norges bank | 34.04K | 0.00% | 34.04K | $506.92K |
Sold Out
| Holder | Change |
|---|---|
| Farther finance advisors | -1.00 |
| Dinuzzo private wealth | -1.00 |
| Sjs investment consulting | -5.00 |
| Mendota financial group | -7.00 |
| Jfs wealth advisors | -7.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 189 | - | 99,642,989 | 2.55% | 93 | 0.96% | 105 | -17.32% | 51 | 70.00% |
| Mar 31, 2025 | 187 | -3.11% | 97,113,724 | 15.75% | 98 | 1.17% | 126 | 44.83% | 30 | -55.22% |
| Dec 31, 2024 | 119 | -37.70% | 59,398,024 | 11.54% | 64 | 1.91% | 52 | -40.91% | 38 | -46.48% |
| Sep 30, 2024 | 190 | -4.52% | 53,251,839 | 2.50% | 58 | 1.79% | 89 | -16.82% | 70 | 16.67% |
| Jun 30, 2024 | 196 | 8.89% | 51,943,543 | -1.54% | 60 | 1.19% | 106 | 27.71% | 59 | 5.36% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.06M | 3.82% | 724.00 |
| Vanguard Total Stock Mkt Idx Inv | 2.11M | 1.98% | -46.72K |
| iShares Russell 2000 ETF | 1.63M | 1.53% | -30.98K |
| Vanguard US Total Market Shares ETF | 1.62M | 1.53% | - |
| Fidelity Select Biotechnology | 1.21M | 1.14% | - |
| SPDR® S&P Biotech ETF | 1.20M | 1.13% | 29.54K |
| Fidelity Select Health Care | 949.76K | 0.90% | - |
| CT (Lux) American Smaller Com 9U USD | 906.88K | 0.86% | 55.03K |
| Fidelity Select Pharmaceuticals Port | 853.52K | 0.81% | - |
| BNP Paribas US Small Cap ClassicC | 790.40K | 0.74% | 2.05K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 05, 2025 | Azoy Alexander | Chief Accounting Officer | Sell | $18.76K |
| Feb 27, 2025 | KANEKO YASUNORI | - | Buy | $201.20K |
| Feb 27, 2025 | ROSEN TERRY J | Chief Executive Officer | Buy | $201.47K |
| Feb 18, 2025 | GILEAD SCIENCES, INC. | - | Buy | $15.00M |
| Dec 31, 2024 | Goeltz II Robert C. | Chief Financial Officer | Sell | $53.91K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | 1 |
| 2025 Q2 | - | - |
| 2025 Q1 | 3 | - |
| 2024 Q4 | - | 2 |
| 2024 Q3 | - | 1 |
RCUS Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools